Introduction
============

Vestibulodynia, also known as provoked localized vulvodynia and formerly termed the "vulvar vestibulitis syndrome," is characterized by a severe, burning/sharp pain that occurs in response to pressure localized to the vulvar vestibule. Vestibulodynia is a common cause of dyspareunia with an estimated prevalence of 15% among women presenting for general gynecologic care \[[@b1]\]. Painful intercourse (dyspareunia) as well as pain with tampon insertion are hallmarks of this condition. Although there are likely multiple causes of vestibular pain, the relationship to combined hormonal contraceptive (CHC) use is becoming increasingly recognized.

Several studies have demonstrated that CHC use significantly increases the risk of developing vestibulodynia \[[@b2]--[@b5]\]. There are several contributing factors that may explain this observation. Due to the fact that CHCs inhibit luteinizing hormone, there is a decreased ovarian production of testosterone. In addition, both the synthetic estrogen and synthetic progestin component of CHCs, which are metabolized in the liver, leads to increased hepatic production of sex hormone binding globulin (SHBG). The combination of lower total testosterone production from the ovaries combined with the increased levels of SHBG in turn lead to decreased levels of circulating free testosterone. It has been suggested that CHC with newer progestins lower free testosterone greater than CHC with the earlier progestins \[[@b6]\].

The vulvar vestibule is embryologically analogous to the male urethra. The mucin-secreting, androgen-dependant Cowper\'s glands and glands of Litre in men are the embryologic analogs to the Bartholin glands and minor vestibular glands in women. It has been shown that these vestibular glands are rich in androgen receptors \[[@b7]\]. In addition to alterations in serum hormone and SHBG levels, CHCs have been shown to induce changes in hormone receptors as well as alter the morphological pattern in the vestibular mucosa \[[@b8]\]. In addition, CHC have been shown to lower the pain threshold of the vulvar vestibule \[[@b9]\].

Interestingly, the vestibule is not the only female genital structure to sustain detrimental effects from CHCs. A recent study assessed the affects of 30 mg ethinyl estradiol and 3 mg drospirenone (Yasmin™, Bayer, Leverkusen, Germany) on the thickness of the labia minora and vaginal introitus area. After only 3 months of use, the subjects experienced worsening of pain with intercourse, decreased thickness of the labia minora, decreased diameter of the vaginal introitus, and decreased size of the glans clitoris in comparison with the baseline values \[[@b10]\]. Bohm-Starke et al. report that some women with vestibulodynia had resolution of symptoms after discontinuing CHC (personal communication).

In 2008, The National Survey of Family Growth found that 82% of American women age 18--44 had used the oral contraceptive pill at some point in their life, and among women under age 30, a higher percentage of women used the pill than any other method of contraception. Although CHCs are highly reliable in the prevention of pregnancy, like any other medication, they have potential side effects. Clinicians must be aware that (ironically) vestibular pain and dyspareunia are potential side effects of CHCs.

The authors have previously hypothesized that CHC that changes to the vestibular mucosa induced by CHCs are a potential cause of vestibulodynia \[[@b11]\]. Herein, we describe our treatment approach to and clinical outcomes in premenopausal women with vestibulodynia who presented to a vulvar pain clinic while currently taking CHCs.

Methods
=======

After obtaining approval from the Anne Arundel Medical Center Institutional Review Board, the database for The Center for Vulvovaginal Disorders was utilized to identify 50 consecutive premenopausal women with vestibulodynia who were using CHCs at the time they presented for care. All women had previously had pain-free intercourse and had subsequently developed vestibular pain (i.e., secondary vestibulodynia). As is our standard practice, all patients were asked to discontinue CHCs, and patients were asked to apply a compounded preparation of topical estradiol 0.03% and testosterone 0.01% to the vestibule twice daily. Testosterone was used in treatment as a recent study examining the impact of vaginal testosterone alone on vaginal atrophy demonstrated improvement in vaginal atrophy symptoms \[[@b12]\].

Patients who had other causes of vestibular pain such as pelvic floor muscle hypertonus, infection, and vulvar dermatoses were excluded from this review; thus, only patients in whom CHCs were the only identifiable cause of their vestibular pain were included. Data abstracted included age, average time taking CHCs, baseline and posttreatment vestibular pain scores, SHBG, and calculated free testosterone levels as well as treatment time (in weeks). Vestibular pain was assessed using a moist cotton swab. If the vestibular pain in a given patient varied at different locations on the vestibule, the highest score was used when calculating the average pre- and postvestibular pain scores. Descriptive statistics and *t*-tests were applied as appropriate.

Results
=======

The average age was 26 years, and the average duration of CHC use was 7 years. The most commonly used CHHs were LoEstrin (Duramed, Tikva, Israel) (n = 6), Yasmin (n = 6), and Yaz (Bayer) (n = 5). Vestibular pain scores decreased from 7.5 to 2 (*P* = 0.001, see Figures [1](#fig01){ref-type="fig"} and [2](#fig02){ref-type="fig"}). Baseline and posttreatment SHBG levels were 154 nmol/L and 64 nmol/L, respectively (*P* = 0.001), and calculated free testosterone levels were 0.193 ng/dL and 0.813 ng/dL, respectively (*P* = 0.001, see Figures [3](#fig03){ref-type="fig"} and [4](#fig04){ref-type="fig"}). The average duration of treatment was 20 weeks.
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Discussion
==========

The potential for negative side effects from CHCs on female sexuality in general is a subject of debate. Perhaps the most widely studied aspect of female sexuality as it relates to CHC use is libido. To date, studies have yielded conflicting results with some studies showing improvement, others a decrease in, and others showing no effect on female desire with CHC use \[[@b13]\]. Interestingly, the proposed explanation of decreased libido in CHC users is the same as what we are hypothesizing causes vestibular pain: elevated SHBG and decrease calculated free testosterone levels.

Although several studies have shown that CHCs increase a woman\'s risk of developing vestibulodynia, other studies have not demonstrated this effect \[[@b14],[@b15]\]. Unfortunately, these studies did not control for the type of CHC used or length of use. Although some studies have assessed hormone receptor expression in the vulvar vestibule and found no difference between women with vestibulodynia and pain-free controls, CHC use was not controlled for \[[@b16]\]. Nevertheless, thousands of women suffer from vestibular pain and are seeking relief. Although there are undoubtedly many causes of vestibular pain, this study provides further evidence to support a hormonally mediated cause, specifically one induced by CHCs. This study has demonstrated that women with vestibulodynia who have no other identifiable cause of their pain that began while taking CHCs are effectively treated by discontinuing the CHCs combined with the application topical hormone therapy. Furthermore, subjective improvement is accompanied by normalization of calculated free testosterone and SHBG values.

Panzer et al. found that in women with sexual dysfunction, SHBG levels in women who discontinued CHCs did not decrease to values of women who never used CHCs \[[@b17]\]. Although the present study noted a marked decrease in SHBG levels, it is unknown if the patients decreased to their baseline level. The hypothesis put forth by Panzer et al. suggesting that prolonged exposure to the synthetic estrogens in CHCs induced gene imprinting and increased gene expression of SHBG in the liver is an interesting one and merits further investigation.

There are many limitations of this study, including those inherent to a retrospective review, the lack of a standardized questionnaire, lack of a standardized instrument to assess vestibular pain (such as a vulvalgesiometer), lack of placebo control, and testosterone levels that were drawn randomly during the menstrual cycle. In addition, subjects effectively underwent three concurrent interventions: cessation of CHC, application of topical estradiol, and the application of topical testosterone. As such, we cannot know the relative importance of each of these three interventions in the patients\' improvement in symptoms. A prospective, randomized, placebo-controlled trial is needed to ascertain if all three components of this treatment regimen are needed to treat women with hormonally mediated vestibulodynia. Therefore, until these trial are completed and despite the aforementioned limitations of this study, we suggest that women with secondary vestibulodynia that developed while on CHC be considered for the treatment approach described in this article.
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